223 related articles for article (PubMed ID: 34434533)
1. Androgens alter the heterogeneity of small extracellular vesicles and the small RNA cargo in prostate cancer.
Martens-Uzunova ES; Kusuma GD; Crucitta S; Lim HK; Cooper C; Riches JE; Azad A; Ochiya T; Boyle GM; Southey MC; Del Re M; Lim R; Ramm GA; Jenster GW; Soekmadji C
J Extracell Vesicles; 2021 Aug; 10(10):e12136. PubMed ID: 34434533
[TBL] [Abstract][Full Text] [Related]
2. Effects of treatment with androgen receptor ligands on microRNA expression of prostate cancer cells.
Segal CV; Koufaris C; Powell C; Gooderham NJ
Toxicology; 2015 Jul; 333():45-52. PubMed ID: 25846647
[TBL] [Abstract][Full Text] [Related]
3. Extracellular Vesicles in the Adaptive Process of Prostate Cancer during Inhibition of Androgen Receptor Signaling by Enzalutamide.
Soekmadji C; Rockstroh A; Ramm GA; Nelson CC; Russell PJ
Proteomics; 2017 Dec; 17(23-24):. PubMed ID: 29105980
[TBL] [Abstract][Full Text] [Related]
4. Targeting androgen receptor (AR) with antiandrogen Enzalutamide increases prostate cancer cell invasion yet decreases bladder cancer cell invasion via differentially altering the AR/circRNA-ARC1/miR-125b-2-3p or miR-4736/PPARγ/MMP-9 signals.
Deng G; Wang R; Sun Y; Huang CP; Yeh S; You B; Feng C; Li G; Ma S; Chang C
Cell Death Differ; 2021 Jul; 28(7):2145-2159. PubMed ID: 34127806
[TBL] [Abstract][Full Text] [Related]
5. Nanoscale flow cytometry to distinguish subpopulations of prostate extracellular vesicles in patient plasma.
Padda RS; Deng FK; Brett SI; Biggs CN; Durfee PN; Brinker CJ; Williams KC; Leong HS
Prostate; 2019 May; 79(6):592-603. PubMed ID: 30680751
[TBL] [Abstract][Full Text] [Related]
6. Plasma extracellular vesicles as phenotypic biomarkers in prostate cancer patients.
Joncas FH; Lucien F; Rouleau M; Morin F; Leong HS; Pouliot F; Fradet Y; Gilbert C; Toren P
Prostate; 2019 Nov; 79(15):1767-1776. PubMed ID: 31475741
[TBL] [Abstract][Full Text] [Related]
7. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen.
Evans MJ; Smith-Jones PM; Wongvipat J; Navarro V; Kim S; Bander NH; Larson SM; Sawyers CL
Proc Natl Acad Sci U S A; 2011 Jun; 108(23):9578-82. PubMed ID: 21606347
[TBL] [Abstract][Full Text] [Related]
8. Role of Testosterone Levels on the Combinatorial Effect of
Pillai P; Pooleri GK; Nair SV
Integr Cancer Ther; 2021; 20():1534735421996824. PubMed ID: 33615860
[TBL] [Abstract][Full Text] [Related]
9. miR-103a-2-5p/miR-30c-1-3p inhibits the progression of prostate cancer resistance to androgen ablation therapy via targeting androgen receptor variant 7.
Chen W; Yao G; Zhou K
J Cell Biochem; 2019 Aug; 120(8):14055-14064. PubMed ID: 30963631
[TBL] [Abstract][Full Text] [Related]
10. Continued androgen signalling inhibition improves cabazitaxel efficacy in prostate cancer.
Mout L; van Royen ME; de Ridder C; Stuurman D; van de Geer WS; Marques R; Buck SAJ; French PJ; van de Werken HJG; Mathijssen RHJ; de Wit R; Lolkema MP; van Weerden WM
EBioMedicine; 2021 Nov; 73():103681. PubMed ID: 34749299
[TBL] [Abstract][Full Text] [Related]
11. A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts.
Markowski MC; Wang H; Sullivan R; Rifkind I; Sinibaldi V; Schweizer MT; Teply BA; Ngomba N; Fu W; Carducci MA; Paller CJ; Marshall CH; Eisenberger MA; Luo J; Antonarakis ES; Denmeade SR
Eur Urol; 2021 May; 79(5):692-699. PubMed ID: 32624280
[TBL] [Abstract][Full Text] [Related]
12. Modulation of paracrine signaling by CD9 positive small extracellular vesicles mediates cellular growth of androgen deprived prostate cancer.
Soekmadji C; Riches JD; Russell PJ; Ruelcke JE; McPherson S; Wang C; Hovens CM; Corcoran NM; ; Hill MM; Nelson CC
Oncotarget; 2017 Aug; 8(32):52237-52255. PubMed ID: 28881726
[TBL] [Abstract][Full Text] [Related]
13. Expression of human prostatic acid phosphatase correlates with androgen-stimulated cell proliferation in prostate cancer cell lines.
Lin MF; Meng TC; Rao PS; Chang C; Schonthal AH; Lin FF
J Biol Chem; 1998 Mar; 273(10):5939-47. PubMed ID: 9488733
[TBL] [Abstract][Full Text] [Related]
14. Functional characterization of androgen receptor in two patient-derived xenograft models of triple negative breast cancer.
Wang X; Petrossian K; Huang MJ; Saeki K; Kanaya N; Chang G; Somlo G; Chen S
J Steroid Biochem Mol Biol; 2021 Feb; 206():105791. PubMed ID: 33271252
[TBL] [Abstract][Full Text] [Related]
15. Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer.
Staniszewska M; Fragoso Costa P; Eiber M; Klose JM; Wosniack J; Reis H; Szarvas T; Hadaschik B; Lückerath K; Herrmann K; Fendler WP; Iking J
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299051
[TBL] [Abstract][Full Text] [Related]
16. Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer.
Fletcher CE; Sulpice E; Combe S; Shibakawa A; Leach DA; Hamilton MP; Chrysostomou SL; Sharp A; Welti J; Yuan W; Dart DA; Knight E; Ning J; Francis JC; Kounatidou EE; Gaughan L; Swain A; Lupold SE; de Bono JS; McGuire SE; Gidrol X; Bevan CL
Oncogene; 2019 Jul; 38(28):5700-5724. PubMed ID: 31043708
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
[TBL] [Abstract][Full Text] [Related]
18. Secreted indicators of androgen receptor activity in breast cancer pre-clinical models.
Hanamura T; Christenson JL; O'Neill KI; Rosas E; Spoelstra NS; Williams MM; Richer JK
Breast Cancer Res; 2021 Nov; 23(1):102. PubMed ID: 34736512
[TBL] [Abstract][Full Text] [Related]
19. Collateral resistance to taxanes in enzalutamide-resistant prostate cancer through aberrant androgen receptor and its variants.
Shiota M; Dejima T; Yamamoto Y; Takeuchi A; Imada K; Kashiwagi E; Inokuchi J; Tatsugami K; Kajioka S; Uchiumi T; Eto M
Cancer Sci; 2018 Oct; 109(10):3224-3234. PubMed ID: 30051622
[TBL] [Abstract][Full Text] [Related]
20. Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer.
Qu F; Xie W; Nakabayashi M; Zhang H; Jeong SH; Wang X; Komura K; Sweeney CJ; Sartor O; Lee GM; Kantoff PW
Clin Cancer Res; 2017 Feb; 23(3):726-734. PubMed ID: 27489290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
